Wellmark

Does Wellmark cover Zepbound?

Quick answer · Weight Loss

Wellmark covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Depends on your plan's benefit. Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

Last verified June 3, 2026. Policy effective May 19, 2026. Source: Drugs-for-weight-loss-management.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, and CVD)
  • 6 months of a documented diet and exercise program
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Weight Loss - Continuation/Already on therapy

All of:

  • Patient is 18 years of age or older
  • Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
  • Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI >= 30

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient has a baseline BMI >= 30 kg/m2
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI >= 27 and comorbidity

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient has a baseline BMI >= 27 kg/m2
  • Patient has at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, or cardiovascular disease)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

  • Chart notes or medical record documentation of Body Mass Index (BMI)
  • Chart notes or medical record documentation of weight-related comorbid condition, if applicable
  • Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

  • All strengths — 4 pens

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
  • Combination use with another targeted weight loss agent
  • Plans without specific benefit language allowing weight loss drug coverage

Policy note: The Zepbound weight_loss and osa indications are covered under a single section IX. The BMI >= 27 with comorbidity pathway for weight loss lists cardiovascular disease as an accepted comorbidity (in addition to hypertension and dyslipidemia), which differs slightly from Wegovy's weight_loss pathway. Members receiving medication via samples or manufacturer patient assistance programs must meet initial approval criteria.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Zepbound for Osa

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition
  • 6 months of a documented diet and exercise program
  • Diagnosed obstructive sleep apnea
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

OSA - Continuation/Already on therapy

All of:

  • Patient is 18 years of age or older
  • Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
  • Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

OSA - New to therapy (primary OSA indication, BMI >= 27)

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient is requesting the medication for the primary indication of Obstructive Sleep Apnea (OSA)
  • Patient has a baseline BMI >= 27 kg/m2
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

  • Chart notes or medical record documentation of Body Mass Index (BMI)
  • Documentation of OSA diagnosis (primary indication)
  • Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

  • All strengths — 4 pens

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
  • Combination use with another targeted weight loss agent
  • Plans without specific benefit language allowing weight loss drug coverage

Policy note: OSA pathway allows a lower BMI threshold of >= 27 kg/m2 (without a separate comorbidity requirement) when requesting for the primary indication of OSA. AHI severity threshold is not specified in this policy. No PAP/CPAP prior trial is required per this policy. The OSA indication is handled within the same section IX as weight loss; both pathways share the same approval durations and continuation criteria. The moderate-to-severe AHI criterion from FDA labeling is not explicitly reproduced in the PA criteria. The T2DM exclusion applies here as the policy states 'Requests for Wegovy or Zepbound for patients with type 2 diabetes mellitus as a comorbid, weight-related condition are excluded from coverage.'

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Why Zepbound requests get denied by Wellmark

Based on what this policy asks for. Fix these before the first submission.

  1. Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Qualifying weight-related condition not documented with its own diagnosis code.
  5. No documented diet and exercise program.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Wellmark has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Employer / Commercial Insurance.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does Wellmark cover Zepbound?
Wellmark covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Zepbound under Wellmark?
For weight loss on Employer / Commercial Insurance plans, Wellmark requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Zepbound approval last with Wellmark?
Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does Wellmark require to renew Zepbound?
At least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal.
What if my plan excludes weight loss medications?
Wellmark has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects Wellmark's written policy as of May 19, 2026, last verified against the source document on June 3, 2026.

Other medications under Wellmark

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Wellmark's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.